

# Pharmacological fMRI: principles and confounds



The banner features a blue background with the Cardiff University logo in the top right corner. The text 'Cardiff University Brain Research Imaging Centre' is centered in white. Below the text is a horizontal strip of four images: a person wearing a red headset, a person lying in an MRI scanner, a person with a head-mounted display, and the exterior of a building. At the bottom right is the CUBRIC School of Psychology logo, and at the bottom center is the website URL.

CARDIFF  
UNIVERSITY  
PRIFYSGOL  
CAERDYDD


Cardiff University Brain  
Research Imaging Centre

[www.cardiff.ac.uk/psych/cubric](http://www.cardiff.ac.uk/psych/cubric)

**CUBRIC**  
School of Psychology

Richard Wise, [wiserg@cardiff.ac.uk](mailto:wiserg@cardiff.ac.uk)

# Overview



- What is pharmacological FMRI
  - Types of phFMRI experiment
- Potential limitations on interpretation
  - Vascular influences e.g. vascular reactivity
  - Changing baseline
- Multi-modal and alternative measurements
  - Cerebral blood flow (CBF)
  - EEG-FMRI
  - metabolism

# PhfMRI: what do we want?

---

- Demonstrate a drug effect on central activity
  - Central penetration?
  - Choosing a dose
- Provide confidence for go/no-go decisions in drug development
- Suggest / confirm a mechanism of action at brain systems level
  - Comparing compounds with different mechanisms
- A neuroscientific tool for modulating brain systems


# BOLD pharmacological fMRI

---

- A BOLD fMRI experiment + drug administration
- Blood Oxygenation Level Dependent Imaging
  - Signal changes are a function of changes in
    - Metabolic oxygen consumption
    - Cerebral blood flow
    - Cerebral blood volume
- Pharmacological modulation of
  - ‘activity’ over pharmacokinetic timescales
  - task-related ‘activity’
  - ‘resting state activity’



# Modulation of baseline activity according to pharmacokinetics

---




# Modulation of baseline activity according to pharmacokinetics

---



# Modulation of baseline activity according to pharmacokinetics

---




- Waveform analysis protocol (WAP) for BOLD signal

# Modulation of baseline activity according to pharmacokinetics

---

- Slow changes in BOLD signal
  - Signal drifts problematic in man
  - More easily applied in animals (phMRI)




- Waveform analysis protocol (WAP) for BOLD signal

# Modulation of baseline activity following psilocybin infusion

---

- Slow changes in BOLD signal modelled from the time-course of subjective effects (approx 10 mins)




- Linear modelling of BOLD signal

# Modulation of baseline activity following psilocybin infusion

---


- Slow changes in BOLD signal modelled from the time-course of subjective effects (approx 10 mins)



- Can also be assessed with arterial spin labelling (ASL) cerebral blood flow (CBF) measurement (more later)
- Linear modelling of BOLD signal

# Modulation of baseline activity following psilocybin infusion


- Slow changes in BOLD signal modelled from the time-course of subjective effects (approx 10 mins)




# Modulation of task-related activity

---

- Stimulus-induced BOLD response




Wise et al Neuropsychopharmacology 2004, **Thermal pain, brain activity**




# Modulation of task-related activity

---


- Stimulus-induced BOLD response - reduced by mu-opioid



Wise et al Neuropsychopharmacology 2004, **Thermal pain, brain activity**



# Time of action: PK/PD measurement



Pre-infusion:  
mean amplitude  
 $S_0$

During-infusion:  
final amplitude  
 $S_1$

Washout:  
modelled amplitude

$$S(t_w) = S_0 - (S_0 - S_1) \cdot \exp(-t_w \cdot \ln 2 / t_{1/2})$$

# Time of action: PK/PD measurement


---

	FMRI signal (insular cortex)	Reported pain intensity
Onset equilibration time $t_{1/2} k_{e0}$ (95%CI) min	1.62 (-2.52, 5.76)	2.80 (-0.12, 5.73)
Offset half-life $t_{1/2}$ (95%CI) min	3.20 (0.58, 5.82)	2.80 (1.12, 4.48)

- Minto et al. Anesthesiology. 1997
- $t_{1/2} k_{e0}$  from: EEG  $1.6 \pm 0.9$  min, analgesia  $1.3 \pm 1.5$  min
- $t_{1/2}$  from: EEG 3-5 min, plasma conc  $3.2 \pm 0.9$  min



# Modulation of resting-state activity

- BOLD signal oscillations implying synchronised network activity (assumed neural)



# Modulation of resting-state activity


- BOLD signal oscillations implying synchronised network activity (assumed neural)
  - Midazolam sedation (Greicius, Hum Brain Mapp, 2008)
    - Altered 'functional connectivity'




# Modulation of resting-state activity

---


- BOLD signal oscillations implying synchronised network activity (assumed neural)
  - Midazolam sedation (Kiviniemi, Magn Reson Imag, 2005)
    - Altered general low frequency BOLD oscillations ... neural or vascular?
    - Vasomotion and CO2 effects



# BOLD FMRI




# What's in an image voxel?





55  $\mu\text{l}$  of stuff


- 3% **vessels**
- $5.5 \times 10^6$  **neurons**
- $5.5 \times 10^{10}$  **synapses**
- 22 km of **dendrites**
- 220 km **axons**

# BOLD: a balance between excitation and inhibition












N = normal response



N = normal response





N = normal response



# Reduced vascular reactivity: aging as an example


---


- Reduced vascular reactivity to a motor stimulus
- Reicker et al 2003 JCBFM
- Altered neurovascular coupling with age



# Baseline perfusion affects BOLD contrast

---






Investigating and controlling such issues ...

# A case study: mu-opioid and pain


---

- Does it produce the expected behavioural effect?
  - Reported pain
- Does this drug globally modulate the BOLD response?
  - A specificity task
- Is there an electrophysiological correlate?
  - EEG, laser evoked potentials
- Does this drug affect vascular reactivity?
  - CO<sub>2</sub> a probe of vascular reactivity


# FMRI of opioid analgesia: reduced pain activity



Perceived pain intensity





# Control task: visual activity, unaffected




Tracey and Wise,  
J Pharm Prac  
2001

# EEG (evoked potentials) consistent with FMRI


---



# Vascular reactivity




# BOLD response to CO<sub>2</sub>




$$\Delta R2^* \propto (1-Y)^\beta \text{ CBV}$$

Y = O<sub>2</sub> saturation  
b ~ 1.5




# BOLD response to CO<sub>2</sub>

---





# Opioids: vascular response to CO<sub>2</sub>

- Test with a global vascular challenge (hypercapnia)



# Test vascular responsiveness with CO<sub>2</sub>




- Pain area
  - anterior cingulate cortex
- BOLD response to CO<sub>2</sub> **unchanged**

# Robustly accounting for vascular reactivity differences using breath-hold

- CO<sub>2</sub> - a global vascular probe
- Breath-hold is easier than feeding in CO<sub>2</sub>
- Aspects of breath-hold (BH) derived BOLD measures are often neglected
  - BH needs to be done in a controlled manner
  - increases in arterial CO<sub>2</sub> due to breath-hold differ between subjects ... factor this in
    - BOLD signal reactivity per mmHg rise in end-tidal CO<sub>2</sub>


# End-tidal CO<sub>2</sub> response to breath-hold

---




- Mean end-tidal CO<sub>2</sub> levels = 39.7 mmHg, range 35.8 – 44.4 mmHg
- End-tidal increases:  $13.4 \pm 2.2$  mmHg (range: 9.5 – 17.3 mmHg)


# Group level model of breath-hold signal change



- Include as a *voxel-dependent* covariate in your group analysis to account for *between-subject/scan* variability

# Group level vascular covariate: motor activity







- BOLD signal provides a measure of short term activity within session relative to the *baseline*
  - % signal change
- What can we do with
  - Changing baseline
  - Longer term changes in 'activity' levels

# Baseline perfusion affects BOLD contrast


---





# Effect of Acetazolamide on fMRI Response


---



20% increase in baseline CBF  
→ no effect on  $\Delta$ CBF with  
finger tapping,

# Effect of Acetazolamide on fMRI Response

---




20% increase in baseline CBF  
→ no effect on  $\Delta$ CBF with  
finger tapping,


→ but BOLD response to finger  
tapping reduced by 35%

# CBF (potentially) a better marker of neural activity

---




Feed-forward mechanism with neural activity driving an increase in CBF



# CBF Measurement: Principles of ASL





---

- Magnetically **label** water in the blood upstream of imaging plane
- **Wait** some period of time for blood to arrive
- **Acquire** images
- **Repeat** procedure in the **absence** of labeled blood





# Typical resting CBF map

---




# Stimulus frequency response of BOLD vs ASL



- 
- CBF measurement can help to interpret task related signal changes

## Cerebral perfusion and oxygenation differences in Alzheimer's disease risk


Adam S. Fleisher<sup>a,\*</sup>, Katherine M. Podraza<sup>a</sup>, Katherine J. Bangen<sup>a</sup>, Curtis Taylor<sup>a</sup>, Ayesha Sherzai<sup>a</sup>, Kunal Sidhar<sup>c</sup>, Thomas T. Liu<sup>b</sup>, Anders M. Dale<sup>a,b</sup>, Richard B. Buxton<sup>b</sup>



- High and low risk of AD
- BOLD and CBF responses to an **associative learning task**
- Resting (baseline) CBF


# BOLD response to task

---



- Less *activity* during task where AD risk higher


# BOLD response to task



- Less *activity* during task where AD risk higher

# ...same perfusion in the active state

---





- Fractional changes in BOLD depend on the state of the brain at rest
- BOLD should not be taken as representing neuronal activity where underlying (neuro)physiology may be altered

# CBF as a marker of drug activity

---

- Where is a drug *likely* to be having an effect?
  - Central penetration
  - Sites of metabolic/neuronal action, downstream of binding
  - Sites of vascular activity
- Back to our opioid analgesics

# Opiate receptor binding potential



# Hypothesis


---

“Where is a drug *likely* to be having an effect?”


A CBF increase in response to remifentanil administration in those areas of high opioid receptor binding potential and networks responding to pain

- ACC, insular, brainstem, thalamus, striatum (deep grey)

# Opioid-induced CBF **increases** and **decreases**



**CO<sub>2</sub> & opioid sensitive brainstem breathing activity**, Pattinson et al Neuroimage & J. Neurosci. 2009




**Pain brainstem activity**, Dunckley et al J. Neurosci. 2005,

insula


# Number of subjects for an ASL perfusion study

---




- 4 minute perfusion scan
- 15-40 subjects per group needed to detect a 15% change in CBF within a region of interest


# Psilocybin effects on perfusion



- Psilocybin - partial agonist of 5-HT<sub>2A</sub> receptor
- Focal perfusion decreases (15 subjects)
- Subjective effects correlate with perfusion decrease in rostral anterior cingulate / medial prefrontal cortex




- Can we get closer to neural activity?
- What if neurovascular coupling / signalling is altered?




# Calibrated FMRI: CMRO<sub>2</sub>

- Measure changes in oxygen consumption (CMRO<sub>2</sub>)
  - Calibrate the BOLD response to a pure change in flow / blood oxygen, *without* change in metabolism
    - Using CO<sub>2</sub> challenge
  - Difference between *calibration* and *task* scan gives relative oxygen metabolism




②

Measure BOLD/CBF response to CO<sub>2</sub>




③

Quantify activation (visual) using model



④


CMRO<sub>2</sub> map



# Drug induced change in vascular response

---


- Indomethacin
  - Non-steroidal anti-**inflammatory** drug
  - Inhibits Cox1 & 2 that participate in prostaglandin synthesis
- Vasoconstrictive effects




# Drug induced change in vascular response

---


- Indomethacin
  - Non-steroidal anti-**inflammatory** drug
  - Inhibits Cox1 & 2 that participate in prostaglandin synthesis
- Vasocostrictive effects




# Reduced vascular response to finger tapping




# $\Delta\text{CMRO}_2$ preserved: a better marker of neural activity





- Direct measures of neuronal activity ...  
electroencephalography



# Caffeine

Neuroexcitatory:  
adenosine  $A_1$  receptors

Vasoconstrictive:  
adenosine  $A_2$  receptors


Neural  
activity

Neurovascular  
coupling




Vascular response

BOLD FMRI


[dHb]



BOLD  
signal



CBF



Perfusion FMRI

# Effects of caffeine on neurovascular coupling

---

- Caffeine decreases cerebral perfusion and acts as a BOLD *contrast booster*
  - Mulderink et al Neuroimage 2002 (oral dose, variable consumers, abstain prior to experiment)
- BOLD response is boosted by caffeine in high users but decreased in low users
  - Laurienti et al Neuroimage 2002
  - receptor expression and affinity are a component of the formation of drug tolerance, which depends on individual caffeine intake
  - Differential weighting of A<sub>1</sub> (neurostimulant) and A<sub>2</sub> (vasoconstrictive) effects according to usage. Field et al Radiology 2003.


# Separating haemodynamic and neuronal effects

---

- In low caffeine consumers we hypothesize that caffeine decreases CBF
  - Pulsed ASL CBF measurements
- We hypothesize a ‘neuronal’ effect of caffeine on a cognitive auditory-oddball task
  - Simultaneous EEG-fMRI, enhanced P300 novelty odd-ball response
- Use cognitively undemanding *control* tasks to identify general vascular influence of caffeine on BOLD contrast
  - Motor and visual

# Caffeine: decreases in grey matter flow

---






# BOLD: Visual stimulus

Placebo


Caffeine

Placebo-Caffeine

VIS




VIS




P<0.05 corrected

# Auditory Oddball (target-nontarget)

Placebo




Caffeine



Caffeine-Placebo

Increased activity at frontal pole




P<0.05 corrected

# Working Memory and Auditory Oddball


---

Caffeine effect on working memory task (n-back)

Koppelstaetter et al. Journal of Alzheimer's disease. In Press



Caffeine-Placebo  
Auditory oddball




P<0.05 corrected

# Caffeine: vascular 'oscillations'

---

Placebo



% temporal standard deviation




# Caffeine: decreases vascular 'oscillations'

---

Placebo

Caffeine




% temporal standard deviation




# Caffeine: decreases vascular 'oscillations'

---


Placebo



Caffeine



Significant Tstd ↓



% temporal standard deviation



P<0.05 corrected

# Caffeine: decreases vascular ‘oscillations’

---

Caffeine reduces resting-state BOLD functional connectivity in the motor cortex


Anna Leigh Rack-Gomer, Joy Liau, Thomas T. Liu \*


*Center for Functional Magnetic Resonance Imaging, University of California San Diego, La Jolla, CA 92093-0677, USA*

*Department of Radiology, University of California San Diego, La Jolla, CA 92093-0677, USA*

*Department of Bioengineering, University of California San Diego, La Jolla, CA 92093-0677, USA*

NeuroImage 46 (2009) 56–63





# Summary: in pharmacological fMRI...

---

- BOLD is rarely enough on its own as there can be problems with interpretation
  - Task related / PK / resting-state functional connectivity
- Measure vascular state
  - Vascular reactivity to aid fMRI interpretation
  - CBF measurement as a marker of
    - Disease, recovery, reorganisation, drug action
    - Aids interpretation of BOLD
  - Metabolism as a marker of neural activity
- EEG (or MEG) for clues over neural effects
- ... these methods are becoming more and more practical for drug and disease studies

# Thanks

---

- UK Medical Research Council (RW)
- CUBRIC
- The Group
  - Ana Diukova
  - Kevin Murphy
  - Ashley Harris
  - Tommaso Gili

